[go: up one dir, main page]

BG62876B1 - Използване на мелатонин за лечение на пациенти,страдащи от лекарствена зависимост - Google Patents

Използване на мелатонин за лечение на пациенти,страдащи от лекарствена зависимост Download PDF

Info

Publication number
BG62876B1
BG62876B1 BG101803A BG10180397A BG62876B1 BG 62876 B1 BG62876 B1 BG 62876B1 BG 101803 A BG101803 A BG 101803A BG 10180397 A BG10180397 A BG 10180397A BG 62876 B1 BG62876 B1 BG 62876B1
Authority
BG
Bulgaria
Prior art keywords
melatonin
benzodiazepine
treatment
daily
use according
Prior art date
Application number
BG101803A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG101803A (en
Inventor
Nava Zisapel
Original Assignee
Neurim Pharmaceuticals (1991) Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/381,535 external-priority patent/US6469044B1/en
Application filed by Neurim Pharmaceuticals (1991) Ltd. filed Critical Neurim Pharmaceuticals (1991) Ltd.
Publication of BG101803A publication Critical patent/BG101803A/xx
Publication of BG62876B1 publication Critical patent/BG62876B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BG101803A 1995-02-01 1997-07-30 Използване на мелатонин за лечение на пациенти,страдащи от лекарствена зависимост BG62876B1 (bg)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/381,535 US6469044B1 (en) 1995-02-01 1995-02-01 Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies
EP95303853A EP0724878B1 (fr) 1995-02-01 1995-06-06 Utilisation de la mélatonine pour traiter les patients souffrant d'une dépendance vis à vis d'une drogue
PCT/IB1996/000082 WO1996023496A1 (fr) 1995-02-01 1996-01-29 Utilisation de la melatonine dans le traitement des patients souffrant d'accoutumance a certaines drogues

Publications (2)

Publication Number Publication Date
BG101803A BG101803A (en) 1998-04-30
BG62876B1 true BG62876B1 (bg) 2000-10-31

Family

ID=26140195

Family Applications (1)

Application Number Title Priority Date Filing Date
BG101803A BG62876B1 (bg) 1995-02-01 1997-07-30 Използване на мелатонин за лечение на пациенти,страдащи от лекарствена зависимост

Country Status (22)

Country Link
JP (1) JP4516159B2 (fr)
CN (1) CN1083263C (fr)
AT (1) AT408188B (fr)
AU (1) AU695366B2 (fr)
BG (1) BG62876B1 (fr)
BR (1) BR9607169A (fr)
CZ (1) CZ291349B6 (fr)
DK (1) DK176081B1 (fr)
EE (1) EE03384B1 (fr)
FI (1) FI119586B (fr)
IS (1) IS1980B (fr)
LU (1) LU90118B1 (fr)
LV (1) LV11940B (fr)
MD (1) MD1716C2 (fr)
NO (1) NO312814B1 (fr)
NZ (1) NZ298878A (fr)
PL (1) PL183148B1 (fr)
SI (1) SI9620022A (fr)
SK (1) SK284521B6 (fr)
TR (1) TR199700723T1 (fr)
TW (1) TW483757B (fr)
WO (1) WO1996023496A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL150190A0 (en) 2000-01-05 2002-12-01 Neurim Pharma 1991 Method and formulation for treating resistance to antihypertensives and related conditions
IL149377A (en) * 2002-04-28 2012-10-31 Neurim Pharma 1991 Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds
US9119846B2 (en) 2003-04-29 2015-09-01 Neurim Pharmaceuticals (1991) Ltd. Method and composition for enhancing cognition in alzheimer's patients
IL155666A (en) 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
KR102411809B1 (ko) 2012-01-26 2022-06-22 반다 파마슈티칼즈, 인코퍼레이티드. 일주기 리듬 장애의 치료
CN110200958A (zh) 2012-12-18 2019-09-06 万达制药公司 昼夜节律紊乱的治疗
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
PT3337462T (pt) * 2016-10-31 2020-10-30 Neurim Pharmaceuticals 1991 Ltd Minicomprimidos de melatonina e método de fabrico dos mesmos

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2134789T3 (es) * 1991-05-09 1999-10-16 Neurim Pharma 1991 Composiciones que contienen melatonina.
IT1251544B (it) * 1991-05-13 1995-05-17 Gabriele Biella Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico

Also Published As

Publication number Publication date
MD1716B2 (en) 2001-08-31
NO312814B1 (no) 2002-07-08
EE9700166A (et) 1998-02-16
SK284521B6 (sk) 2005-05-05
TW483757B (en) 2002-04-21
SI9620022A (sl) 1998-10-31
IS4532A (is) 1997-07-25
PL183148B1 (pl) 2002-05-31
MD970254A (en) 1999-05-31
NO973531L (no) 1997-09-30
AU695366B2 (en) 1998-08-13
BG101803A (en) 1998-04-30
LU90118B1 (fr) 1997-11-13
BR9607169A (pt) 1997-11-11
AT408188B (de) 2001-09-25
CN1083263C (zh) 2002-04-24
AU4457496A (en) 1996-08-21
MD1716C2 (ro) 2002-02-28
MX9705856A (es) 1998-07-31
PL321630A1 (en) 1997-12-08
CZ240597A3 (cs) 1998-01-14
FI973185A0 (fi) 1997-07-31
JP4516159B2 (ja) 2010-08-04
FI973185A (fi) 1997-09-30
WO1996023496A1 (fr) 1996-08-08
FI119586B (fi) 2009-01-15
DK89697A (da) 1997-07-30
IS1980B (is) 2005-01-14
CZ291349B6 (cs) 2003-02-12
LV11940A (lv) 1998-01-20
SK103097A3 (en) 1998-01-14
NZ298878A (en) 1999-05-28
ATA901396A (de) 2001-02-15
TR199700723T1 (xx) 1998-02-21
LV11940B (en) 1998-05-20
DK176081B1 (da) 2006-04-18
CN1172431A (zh) 1998-02-04
JPH10513177A (ja) 1998-12-15
NO973531D0 (no) 1997-07-31
EE03384B1 (et) 2001-04-16

Similar Documents

Publication Publication Date Title
US11241429B2 (en) Method of treating metabolic disorders and depression with dopamine receptor agonists
LT3893B (en) Pharmaceutical composition with nalmefene for treating alcoholism
EP0724878B1 (fr) Utilisation de la mélatonine pour traiter les patients souffrant d'une dépendance vis à vis d'une drogue
US20030008005A1 (en) Sublingual administration of dihydroergotamine for the treatment of migraine
BG62876B1 (bg) Използване на мелатонин за лечение на пациенти,страдащи от лекарствена зависимост
US5830895A (en) Methods for the determination and adjustment of prolactin daily rhythms
Dépôt et al. Acute and chronic role of 5-HT3 neuronal system on behavioral and neuroendocrine changes induced by intravenous cholecystokinin tetrapeptide administration in humans
EP2138174A1 (fr) Composition pharmaceutique sous forme de comprimé sublingual comprenant un anti-inflammatoire non stéroïdien et un analgésique opiacé pour la gestion de la douleur
Linnoila et al. How to antagonize ethanol-induced inebriation
CA2211839C (fr) Utilisation de la melatonine dans le traitement des patients souffrant d'accoutumance a certaines drogues
AU3101395A (en) Improved methods for the determination and adjustment of prolactin daily rhythms
Wurtman Ramelteon: a melatonin receptor agonist
MXPA97005856A (en) Use of melatonine in the manufacture of unmedicament to deal with addiction to dro
KR20100055428A (ko) 수면 장애의 치료